Position
Squarepoint Ops LLC in Kalaris Therapeutics, Inc.
Back to the book · All holders of KLRS
Estimated mark uses implied 13F prices (value ÷ shares). Adds are treated as happening at this quarter’s mark; cuts at last quarter’s. Share jumps can be splits, not buys. This is not realized P&L.
Latest estimated mark −$67.7K$8.44 → $5.77
| Quarter | Shares | Value | Implied px | Est. mark | Flow | Weight |
|---|---|---|---|---|---|---|
| Q4 2025 | 25.4K | $214.1K | — | — | — | 0.0% |
| Q1 2026 | 39.8K | $229.5K | $5.77 | −$67.7K | $83.1K | 0.0% |